Madrigal Pharmaceuticals, Inc. (MDGL)
USD 314.54
(-3.84%)
USD 314.54
(-3.84%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 17.27 Million USD | 106.13% |
| 2022 | -281.65 Million USD | -694.03% |
| 2021 | -35.47 Million USD | 33.35% |
| 2020 | -53.21 Million USD | -15.64% |
| 2019 | -46.02 Million USD | 90.49% |
| 2018 | -483.71 Million USD | -152.56% |
| 2017 | -191.52 Million USD | -372.92% |
| 2016 | -40.49 Million USD | -33.59% |
| 2015 | -30.31 Million USD | 5.61% |
| 2014 | -32.11 Million USD | -28.0% |
| 2013 | -25.09 Million USD | 63.69% |
| 2012 | -69.11 Million USD | -414.71% |
| 2011 | -13.42 Million USD | 30.85% |
| 2010 | -19.41 Million USD | 53.87% |
| 2009 | -42.09 Million USD | -1.26% |
| 2008 | -41.56 Million USD | 62.33% |
| 2007 | -110.35 Million USD | -291.51% |
| 2006 | -28.18 Million USD | -59.84% |
| 2005 | -17.63 Million USD | 57.0% |
| 2004 | -41.01 Million USD | -13.72% |
| 2003 | -36.06 Million USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -504.79 Million USD | -3021.61% |
| 2024 Q3 | -231.8 Million USD | 70.24% |
| 2024 Q2 | -381.53 Million USD | 24.42% |
| 2023 Q2 | 22.46 Million USD | 178.3% |
| 2023 FY | 17.27 Million USD | 106.13% |
| 2023 Q1 | -28.69 Million USD | 89.81% |
| 2023 Q3 | 54.5 Million USD | 142.65% |
| 2023 Q4 | 17.27 Million USD | -68.3% |
| 2022 Q3 | -9.52 Million USD | -168.72% |
| 2022 Q4 | -281.65 Million USD | -2856.73% |
| 2022 FY | -281.65 Million USD | -694.03% |
| 2022 Q2 | -3.54 Million USD | 91.48% |
| 2022 Q1 | -41.58 Million USD | -17.24% |
| 2021 Q2 | -32.54 Million USD | 25.19% |
| 2021 Q1 | -43.49 Million USD | 18.26% |
| 2021 Q3 | -48.27 Million USD | -48.35% |
| 2021 Q4 | -35.47 Million USD | 26.52% |
| 2021 FY | -35.47 Million USD | 33.35% |
| 2020 FY | -53.21 Million USD | -15.64% |
| 2020 Q4 | -53.21 Million USD | 50.84% |
| 2020 Q2 | -61.34 Million USD | 7.12% |
| 2020 Q1 | -66.05 Million USD | -43.53% |
| 2020 Q3 | -108.25 Million USD | -76.47% |
| 2019 FY | -46.02 Million USD | 90.49% |
| 2019 Q2 | -71.68 Million USD | -53.85% |
| 2019 Q3 | -88.73 Million USD | -23.79% |
| 2019 Q1 | -46.59 Million USD | 90.37% |
| 2019 Q4 | -46.02 Million USD | 48.14% |
| 2018 Q3 | -38.04 Million USD | 85.64% |
| 2018 Q1 | -38.12 Million USD | 80.09% |
| 2018 FY | -483.71 Million USD | -152.56% |
| 2018 Q2 | -264.86 Million USD | -594.72% |
| 2018 Q4 | -483.71 Million USD | -1171.4% |
| 2017 Q4 | -191.52 Million USD | -1377.83% |
| 2017 Q2 | -34.79 Million USD | -323.58% |
| 2017 Q1 | -8.21 Million USD | 79.72% |
| 2017 FY | -191.52 Million USD | -372.92% |
| 2017 Q3 | -12.96 Million USD | 62.76% |
| 2016 Q3 | -8.39 Million USD | 21.73% |
| 2016 FY | -40.49 Million USD | -33.59% |
| 2016 Q4 | -40.49 Million USD | -382.52% |
| 2016 Q1 | -40.48 Million USD | -33.54% |
| 2016 Q2 | -10.72 Million USD | 73.51% |
| 2015 Q3 | -38.57 Million USD | -69.75% |
| 2015 Q4 | -30.31 Million USD | 21.4% |
| 2015 FY | -30.31 Million USD | 5.61% |
| 2015 Q2 | -22.72 Million USD | -4.9% |
| 2015 Q1 | -21.66 Million USD | 32.56% |
| 2014 Q4 | -32.11 Million USD | 38.54% |
| 2014 Q1 | -31.13 Million USD | -24.09% |
| 2014 Q2 | -78.28 Million USD | -151.43% |
| 2014 Q3 | -52.26 Million USD | 33.24% |
| 2014 FY | -32.11 Million USD | -28.0% |
| 2013 Q1 | -11.32 Million USD | 83.61% |
| 2013 FY | -25.09 Million USD | 63.69% |
| 2013 Q4 | -25.09 Million USD | -1175.0% |
| 2013 Q3 | -1.96 Million USD | 80.42% |
| 2013 Q2 | -10.05 Million USD | 11.24% |
| 2012 Q1 | -18.05 Million USD | -34.48% |
| 2012 Q3 | -15.07 Million USD | -62.82% |
| 2012 Q4 | -69.11 Million USD | -358.56% |
| 2012 FY | -69.11 Million USD | -414.71% |
| 2012 Q2 | -9.25 Million USD | 48.74% |
| 2011 Q3 | -3.83 Million USD | 57.02% |
| 2011 FY | -13.42 Million USD | 30.85% |
| 2011 Q4 | -13.42 Million USD | -249.75% |
| 2011 Q2 | -8.93 Million USD | -3750.0% |
| 2011 Q1 | -232 Thousand USD | 98.81% |
| 2010 Q4 | -19.41 Million USD | 8.67% |
| 2010 Q3 | -21.25 Million USD | 48.42% |
| 2010 FY | -19.41 Million USD | 53.87% |
| 2010 Q2 | -41.21 Million USD | 26.67% |
| 2010 Q1 | -56.2 Million USD | -33.52% |
| 2009 Q1 | -29.02 Million USD | 30.19% |
| 2009 Q3 | -32.35 Million USD | -12.03% |
| 2009 Q4 | -42.09 Million USD | -30.08% |
| 2009 FY | -42.09 Million USD | -1.26% |
| 2009 Q2 | -28.88 Million USD | 0.47% |
| 2008 Q1 | -94.24 Million USD | 14.6% |
| 2008 Q4 | -41.56 Million USD | 22.57% |
| 2008 FY | -41.56 Million USD | 62.33% |
| 2008 Q3 | -53.68 Million USD | 27.41% |
| 2008 Q2 | -73.96 Million USD | 21.52% |
| 2007 FY | -110.35 Million USD | -291.51% |
| 2007 Q1 | -71.06 Million USD | -152.1% |
| 2007 Q2 | -58.81 Million USD | 17.23% |
| 2007 Q4 | -110.35 Million USD | -158.13% |
| 2007 Q3 | -42.75 Million USD | 27.31% |
| 2006 Q3 | -36.11 Million USD | 0.0% |
| 2006 Q4 | -28.18 Million USD | 21.94% |
| 2006 FY | -28.18 Million USD | -59.84% |
| 2005 Q4 | -17.63 Million USD | 0.0% |
| 2005 Q1 | -24.17 Million USD | 0.0% |
| 2005 FY | -17.63 Million USD | 57.0% |
| 2004 FY | -41.01 Million USD | -13.72% |
| 2003 FY | -36.06 Million USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 130.887% |
| Alkermes plc | -166.73 Million USD | 110.362% |
| Agenus Inc. | 274.13 Million USD | 93.697% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 99.076% |
| Aptorum Group Limited | 1.35 Million USD | -1173.207% |
| Ardelyx, Inc. | 34.51 Million USD | 49.936% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | -303.692% |
| Bicycle Therapeutics plc | -481.46 Million USD | 103.589% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 52.222% |
| ChromaDex Corporation | -24.04 Million USD | 171.848% |
| Chimerix, Inc. | -25.51 Million USD | 167.712% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -147.959% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 172.974% |
| CRISPR Therapeutics AG | -150.84 Million USD | 111.454% |
| Precision BioSciences, Inc. | -85.41 Million USD | 120.229% |
| Dyadic International, Inc. | -6.37 Million USD | 370.896% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 208.442% |
| Fortress Biotech, Inc. | 7.66 Million USD | -125.414% |
| Lantern Pharma Inc. | -21.7 Million USD | 179.61% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 115.631% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 302.243% |
| Incyte Corporation | -3.17 Billion USD | 100.544% |
| IO Biotech, Inc. | -140.69 Million USD | 112.28% |
| Jaguar Health, Inc. | 29.39 Million USD | 41.213% |
| Novavax, Inc. | -298.29 Million USD | 105.792% |
| Janux Therapeutics, Inc. | 5.33 Million USD | -223.74% |
| Opthea Limited | 28.15 Million USD | 38.638% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 202.913% |
| ContextLogic Inc. | -232 Million USD | 107.447% |
| MiMedx Group, Inc. | -33.9 Million USD | 150.966% |
| Pyxis Oncology, Inc. | 10.19 Million USD | -69.475% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 845.697% |
| NextCure, Inc. | -6.47 Million USD | 366.759% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 134.213% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 370.858% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | -42.051% |
| Vaxcyte, Inc. | -368.22 Million USD | 104.692% |
| PDS Biotechnology Corporation | -32.7 Million USD | 152.824% |
| Pharming Group N.V. | 109.8 Million USD | 84.265% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 199.322% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 109.86% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 193.294% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 193.294% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 343.352% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 394.846% |
| Acelyrin, Inc. | -216.9 Million USD | 107.966% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 407.971% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 1102.204% |
| Summit Therapeutics Inc. | 34.67 Million USD | 50.17% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 353.976% |
| Senti Biosciences, Inc. | 1.74 Million USD | -892.989% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 109.359% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 122.308% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 385.021% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -17218.005% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -2651.274% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 114.762% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 110.27% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 84.416% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 327.462% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 113.382% |
| Psyence Biomedical Ltd. | 6.89 Million USD | -150.602% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 107.129% |
| Immix Biopharma, Inc. | -17.5 Million USD | 198.676% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 105.456% |
| MEI Pharma, Inc. | -3.7 Million USD | 566.343% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | -38.102% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 89.318% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | 37.833% |
| Fortress Biotech, Inc. | 7.66 Million USD | -125.414% |
| Precigen, Inc. | -481 Thousand USD | 3692.1% |
| Clearside Biomedical, Inc. | 14.08 Million USD | -22.704% |
| AlloVir, Inc. | -62.69 Million USD | 127.56% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 131.068% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 71.981% |
| ImmuCell Corporation | 10.99 Million USD | -57.208% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 111.209% |
| Onconetix, Inc. | 5.33 Million USD | -224.078% |
| PureTech Health plc | -167.19 Million USD | 110.334% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 156.724% |
| Elevation Oncology, Inc. | -19.11 Million USD | 190.376% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 451.966% |
| Seer, Inc. | -4.24 Million USD | 507.5% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 171.881% |
| Innoviva, Inc. | 255.56 Million USD | 93.239% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 130.929% |
| ESSA Pharma Inc. | -33.62 Million USD | 151.39% |
| GlycoMimetics, Inc. | -40.98 Million USD | 142.157% |
| GT Biopharma, Inc. | -1.02 Million USD | 1792.262% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 125.49% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 71.794% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 112.886% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 224.697% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 159.843% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 23035.195% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 155.985% |
| Aptose Biosciences Inc. | -8.19 Million USD | 310.84% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 652.186% |
| Soligenix, Inc. | -4.95 Million USD | 448.938% |
| Century Therapeutics, Inc. | 847 Thousand USD | -1939.906% |
| Kura Oncology, Inc. | -20.11 Million USD | 185.883% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 142.218% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 305.739% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -848.457% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 640.444% |
| Autolus Therapeutics plc | -186.59 Million USD | 109.259% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 135.044% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 106.265% |
| Eterna Therapeutics Inc. | 34.26 Million USD | 49.58% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 89.488% |
| GRI Bio, Inc. | -1.79 Million USD | 1063.099% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 292.34% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 151.953% |
| IGM Biosciences, Inc. | -72.6 Million USD | 123.797% |
| INmune Bio, Inc. | -25.41 Million USD | 167.994% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 88.554% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 134.106% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 206.33% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 698.906% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 54.55% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 141.952% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 45.812% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 95.429% |
| Verastem, Inc. | -37.27 Million USD | 146.349% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 290.433% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 133.315% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 214.159% |
| Histogen Inc. | -7.48 Million USD | 330.773% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 179.965% |
| Surrozen, Inc. | -32.66 Million USD | 152.896% |
| Organovo Holdings, Inc. | -1.5 Million USD | 1246.516% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 511.04% |
| Ovid Therapeutics Inc. | 18.96 Million USD | 8.872% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -560.474% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | -315.736% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 306.153% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 139.773% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 218.53% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 105.454% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 2492.876% |
| Apollomics, Inc. | -27.39 Million USD | 163.07% |
| Amarin Corporation plc | -191.04 Million USD | 109.044% |
| Mesoblast Limited | 55.96 Million USD | 69.126% |
| Turnstone Biologics Corp. | -14.58 Million USD | 218.472% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 168.314% |
| Synaptogenix, Inc. | -28.66 Million USD | 160.283% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 1945.94% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 64.545% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 2104.201% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 337.79% |
| Exelixis, Inc. | -73.05 Million USD | 123.652% |
| Better Therapeutics, Inc. | -860 Thousand USD | 2109.07% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 171.953% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 107.158% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -2247.344% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 332.289% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -1277.831% |
| Gritstone bio, Inc. | 39.49 Million USD | 56.247% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 120.544% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 756.424% |
| Avid Bioservices, Inc. | 169.72 Million USD | 89.82% |
| Insmed Incorporated | 721.62 Million USD | 97.606% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 289.006% |
| MediWound Ltd. | -5.32 Million USD | 424.652% |
| OmniAb, Inc. | 9.2 Million USD | -87.743% |
| Alector, Inc. | -35.63 Million USD | 148.483% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 79.903% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 450.609% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | -30.508% |
| Zai Lab Limited | -775 Million USD | 102.229% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 94.927% |
| Aura Biosciences, Inc. | -21.52 Million USD | 180.269% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 120.948% |
| Immunic, Inc. | -45.34 Million USD | 138.108% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 108.942% |
| Veracyte, Inc. | -203.82 Million USD | 108.477% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 97.293% |
| FibroGen, Inc. | 56.76 Million USD | 69.563% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -94.026% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 711.16% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 934.546% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 99.624% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 617.151% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 110.411% |
| TG Therapeutics, Inc. | 17.86 Million USD | 3.27% |
| Galecto, Inc. | -21.21 Million USD | 181.439% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 172.642% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 98.899% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 170.603% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 250.152% |
| XBiotech Inc. | -200.02 Million USD | 108.638% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 120.544% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | -281.581% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 148.998% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 122.376% |
| Theravance Biopharma, Inc. | 5.69 Million USD | -203.602% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 110.139% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 118.704% |
| Vaxxinity, Inc. | 10.13 Million USD | -70.529% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 97.653% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 260.464% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 126.196% |
| NexImmune, Inc. | -3.13 Million USD | 651.371% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 600.424% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 214.337% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 163.756% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 292.49% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 13969.556% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 142.586% |
| Ainos, Inc. | 4.07 Million USD | -323.696% |
| Pluri Inc. | 22.82 Million USD | 24.316% |
| Prothena Corporation plc | -608.34 Million USD | 102.84% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 114.549% |
| Celularity Inc. | 65.19 Million USD | 73.496% |
| Rallybio Corporation | -24.1 Million USD | 171.687% |
| Cue Biopharma, Inc. | -33.81 Million USD | 151.09% |
| MeiraGTx Holdings plc | -40.3 Million USD | 142.871% |
| Omeros Corporation | 331.17 Million USD | 94.783% |
| Humacyte, Inc. | -22.48 Million USD | 176.839% |
| Immunocore Holdings plc | -358.59 Million USD | 104.818% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 170.307% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 155.914% |
| Blueprint Medicines Corporation | 702.83 Million USD | 97.542% |
| CalciMedica, Inc. | -5.53 Million USD | 412.441% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 109.18% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 269.16% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 143.155% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 151.959% |
| Pulmatrix, Inc. | -10.41 Million USD | 265.863% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 389.075% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 145.299% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 115.51% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 128.824% |
| Cytokinetics, Incorporated | 642.37 Million USD | 97.31% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 396.72% |
| Nutriband Inc. | -251.65 Thousand USD | 6965.694% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 150.64% |
| Vor Biopharma Inc. | 4.3 Million USD | -301.814% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 100.286% |
| Evogene Ltd. | -19.63 Million USD | 188.0% |
| ProKidney Corp. | -56.23 Million USD | 130.724% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 135.499% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 287.048% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 98.733% |
| CorMedix Inc. | -43.05 Million USD | 140.132% |
| BioLineRx Ltd. | 7.33 Million USD | -135.523% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 162.909% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 62.559% |
| Atai Life Sciences N.V. | -28.55 Million USD | 160.501% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -674.614% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 175.728% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | 2.577% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 123.015% |
| MediciNova, Inc. | -50.78 Million USD | 134.023% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 121.925% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 76908.18% |
| GeoVax Labs, Inc. | -6.45 Million USD | 367.768% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 108.647% |
| Biomea Fusion, Inc. | -166.57 Million USD | 110.373% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 109.654% |
| Mereo BioPharma Group plc | -51.46 Million USD | 133.57% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 118.217% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 105.882% |
| Absci Corporation | -72.59 Million USD | 123.8% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -278.406% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 107.37% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 118.34% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 118.055% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 144.22% |
| Allakos Inc. | -24.97 Million USD | 169.181% |
| Imunon, Inc. | -4.21 Million USD | 510.029% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 217.203% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 112.761% |
| BioAtla, Inc. | -109.01 Million USD | 115.85% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -2247.344% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 1940.043% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | -44.392% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 181.488% |
| XOMA Corporation | -29 Million USD | 159.579% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 204.336% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 291.637% |
| aTyr Pharma, Inc. | -7.44 Million USD | 331.951% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 113.863% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 108.3% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 121.128% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 118.626% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 2110.978% |
| Akari Therapeutics, Plc | -3.84 Million USD | 549.363% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -964.644% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 98.749% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 1554.212% |
| UroGen Pharma Ltd. | 4.39 Million USD | -293.487% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 84.775% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -23909.894% |
| Orgenesis Inc. | 21.78 Million USD | 20.685% |
| Entera Bio Ltd. | -10.62 Million USD | 262.555% |
| GH Research PLC | -78.07 Million USD | 122.129% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 177.522% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 164.811% |
| Xencor, Inc. | 29.64 Million USD | 41.715% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 977.14% |
| Replimune Group, Inc. | 1.41 Million USD | -1123.654% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 7154.894% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 113.667% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 1554.212% |
| Portage Biotech Inc. | -4.98 Million USD | 446.878% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 76908.18% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 126.13% |
| OncoCyte Corporation | -6.56 Million USD | 363.264% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -1825.312% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 479.266% |
| Purple Biotech Ltd. | -14.13 Million USD | 222.21% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 172.731% |
| scPharmaceuticals Inc. | -6.54 Million USD | 363.988% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 203.51% |
| HilleVax, Inc. | -165.48 Million USD | 110.441% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 780.772% |
| Tharimmune, Inc. | -10.93 Million USD | 258.001% |
| Genprex, Inc. | -6.73 Million USD | 356.44% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 104.685% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 119.532% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 1333.262% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 620.901% |
| OKYO Pharma Limited | -826.84 Thousand USD | 2189.622% |
| Savara Inc. | 153 Thousand USD | -11192.81% |
| Curis, Inc. | -23.88 Million USD | 172.332% |
| Daré Bioscience, Inc. | -5.15 Million USD | 434.981% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 2326.512% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 378.318% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -1358.059% |
| BeiGene, Ltd. | -2.25 Billion USD | 100.767% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | -40.033% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 102.841% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 109.31% |
| Erasca, Inc. | -37.21 Million USD | 146.426% |
| bluebird bio, Inc. | 108.57 Million USD | 84.086% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 1441.571% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 95.438% |
| DBV Technologies S.A. | -126.98 Million USD | 113.606% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 1441.571% |
| Moderna, Inc. | -2.9 Billion USD | 100.594% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 266.905% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 258.98% |
| Molecular Templates, Inc. | 707 Thousand USD | -2343.847% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 155.076% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 95.015% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 121.055% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 118.836% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 153.539% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 150.262% |
| MacroGenics, Inc. | -66.98 Million USD | 125.794% |
| RenovoRx, Inc. | -1.17 Million USD | 1572.975% |
| Adicet Bio, Inc. | -138.78 Million USD | 112.449% |
| Prime Medicine, Inc. | -27.94 Million USD | 161.837% |
| Aditxt, Inc. | 18.12 Million USD | 4.651% |
| Adagene Inc. | -87.62 Million USD | 119.718% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 514.795% |
| Quantum-Si incorporated | -118.55 Million USD | 114.574% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 52.012% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 331.169% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 135.618% |
| SciSparc Ltd. | -2.06 Million USD | 936.707% |
| Vericel Corporation | 1.27 Million USD | -1253.015% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 244.083% |
| Minerva Neurosciences, Inc. | 41 Million USD | 57.863% |
| Generation Bio Co. | 31.44 Million USD | 45.059% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 109.853% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 155.874% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 85.181% |
| Invivyd, Inc. | -198.47 Million USD | 108.705% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 119.14% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 820.611% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 124.407% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 353.158% |
| 2seventy bio, Inc. | 181.71 Million USD | 90.492% |
| ADMA Biologics, Inc. | 90.06 Million USD | 80.816% |
| Clene Inc. | 3.34 Million USD | -417.305% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 290.23% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 180.322% |
| GeoVax Labs, Inc. | -6.45 Million USD | 367.768% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 105.021% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 166.455% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 90.275% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 522.283% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -245.422% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 431.695% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 113.26% |
| Evaxion Biotech A/S | 5.28 Million USD | -226.811% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 115.349% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 113.162% |
| Trevena, Inc. | 2.25 Million USD | -665.19% |
| Surrozen, Inc. | -32.66 Million USD | 152.896% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 133.543% |
| Cingulate Inc. | 3.08 Million USD | -460.486% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 688.287% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -140.406% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 285.96% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 121.782% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 113.144% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 116.371% |
| Clearmind Medicine Inc. | -3.94 Million USD | 538.235% |
| Kronos Bio, Inc. | -36.05 Million USD | 147.923% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | -83.633% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -1084.945% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 131.845% |
| Statera Biopharma, Inc. | 14.41 Million USD | -19.85% |
| ImmunityBio, Inc. | 618.22 Million USD | 97.205% |
| Korro Bio, Inc. | -132.94 Million USD | 112.997% |
| Kineta, Inc. | -4.54 Million USD | 480.489% |
| BioVie Inc. | -17.73 Million USD | 197.438% |
| Codexis, Inc. | -43.27 Million USD | 139.93% |
| Celularity Inc. | 65.19 Million USD | 73.496% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 645.219% |
| Celcuity Inc. | 6.78 Million USD | -154.706% |
| Virax Biolabs Group Limited | -3.36 Million USD | 613.471% |
| Cibus, Inc. | -8.07 Million USD | 313.89% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 508.56% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -278.074% |
| IN8bio, Inc. | -16.38 Million USD | 205.424% |
| Kodiak Sciences Inc. | -103.87 Million USD | 116.633% |
| Annexon, Inc. | -193.75 Million USD | 108.917% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -47894.444% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 198.737% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 591.83% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 98.361% |
| Eyenovia, Inc. | 1.25 Million USD | -1272.684% |
| Puma Biotechnology, Inc. | 26.9 Million USD | 35.781% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 632.778% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 151.969% |
| Arcellx, Inc. | -296.95 Million USD | 105.818% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 188.578% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 129.347% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 183.36% |
| Moolec Science SA | 117.61 Thousand USD | -14590.178% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 144.996% |
| Geron Corporation | 14.76 Million USD | -17.052% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 145.567% |
| Royalty Pharma plc | 5.65 Billion USD | 99.695% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 112.217% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 347.202% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 422.179% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 112.277% |
| Humacyte, Inc. | -22.48 Million USD | 176.839% |
| Structure Therapeutics Inc. | -124.33 Million USD | 113.896% |
| 89bio, Inc. | -289.05 Million USD | 105.977% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 168.449% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 1069.041% |
| Genelux Corporation | -6.89 Million USD | 350.442% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 155.63% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 79.332% |
| Notable Labs, Ltd. | -9.77 Million USD | 276.739% |
| Liquidia Corporation | -80.17 Million USD | 121.55% |
| Mustang Bio, Inc. | -3.73 Million USD | 562.473% |
| Immunovant, Inc. | -635.22 Million USD | 102.72% |
| Quantum-Si incorporated | -118.55 Million USD | 114.574% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 198.372% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 517.041% |
| Vera Therapeutics, Inc. | 8.02 Million USD | -115.249% |
| Acasti Pharma Inc. | -23 Million USD | 175.105% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 613.122% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 206.33% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 112.544% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 654.429% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 177.717% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 193.048% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 110.207% |
| PepGen Inc. | -60.67 Million USD | 128.479% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 175.2% |
| United Therapeutics Corporation | -507.7 Million USD | 103.403% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 190.338% |
| Solid Biosciences Inc. | -47.75 Million USD | 136.184% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 2104.201% |
| Immuneering Corporation | -54.94 Million USD | 131.447% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 511.04% |
| Silo Pharma, Inc. | -3.52 Million USD | 590.252% |
| Belite Bio, Inc | -87.27 Million USD | 119.798% |
| XOMA Corporation | -29 Million USD | 159.579% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 124.44% |
| Bionomics Limited | 227 Million USD | 92.389% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 114.859% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 782.116% |
| uniQure N.V. | -102.95 Million USD | 116.783% |
| Cassava Sciences, Inc. | -121.13 Million USD | 114.263% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 514.795% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 57.808% |
| Forte Biosciences, Inc. | -11.96 Million USD | 244.453% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 658.4% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -16200.0% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 632.778% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -94.026% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 332.983% |
| Altimmune, Inc. | -134.48 Million USD | 112.847% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 91.277% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 782.116% |
| Compugen Ltd. | -12.9 Million USD | 233.896% |
| Peak Bio, Inc. | 10.34 Million USD | -67.096% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 6205.3% |
| Benitec Biopharma Inc. | -50.58 Million USD | 134.158% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 116.56% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | 12.049% |
| Zura Bio Limited | -99.8 Million USD | 117.312% |
| PolyPid Ltd. | 6.17 Million USD | -180.032% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 76.689% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | 12.049% |
| Instil Bio, Inc. | 75.35 Million USD | 77.072% |
| argenx SE | -2.02 Billion USD | 100.852% |
| Immunome, Inc. | -97.02 Million USD | 117.807% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 176.808% |
| Verona Pharma plc | -220.44 Million USD | 107.838% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 124.083% |
| Shattuck Labs, Inc. | -121.42 Million USD | 114.229% |
| CervoMed Inc. | -7.79 Million USD | 321.716% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 109.314% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 495.106% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 113.115% |
| Moolec Science SA | 117.61 Thousand USD | -14590.178% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 855.165% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | -8.678% |
| AnaptysBio, Inc. | -18.15 Million USD | 195.19% |
| Design Therapeutics, Inc. | -18.15 Million USD | 195.196% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 124.549% |
| NeurAxis, Inc. | 145.7 Thousand USD | -11758.614% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | -53.828% |
| Lumos Pharma, Inc. | -28.49 Million USD | 160.639% |
| Achilles Therapeutics plc | -126.92 Million USD | 113.613% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 124.083% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 2734.926% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 183.172% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -1084.945% |
| Nutriband Inc. | -251.65 Thousand USD | 6965.694% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 231.182% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 332.231% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 94.921% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | 27.205% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 103.861% |
| Palisade Bio, Inc. | -12.06 Million USD | 243.231% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 112.314% |
| Beam Therapeutics Inc. | -262.72 Million USD | 106.577% |
| Neurogene Inc. | -131.95 Million USD | 113.094% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | 20.801% |
| AEON Biopharma, Inc. | -4.88 Million USD | 454.057% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 104.581% |
| Sesen Bio, Inc. | -112.55 Million USD | 115.351% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 117.302% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 835.925% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 144.273% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 120.746% |
| Athira Pharma, Inc. | -88.99 Million USD | 119.414% |
| Vaccinex, Inc. | -1.28 Million USD | 1441.46% |
| HCW Biologics Inc. | 2.85 Million USD | -504.829% |
| XOMA Corporation | -29 Million USD | 159.579% |
| Nektar Therapeutics | 210.24 Million USD | 91.782% |
| Arvinas, Inc. | -313.8 Million USD | 105.506% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -964.644% |
| Merus N.V. | -192.88 Million USD | 108.958% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 71.196% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 349.034% |
| Rezolute, Inc. | -68.16 Million USD | 125.346% |
| Clene Inc. | 3.34 Million USD | -417.305% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 231.023% |
| BeyondSpring Inc. | -13.75 Million USD | 225.613% |
| Synlogic, Inc. | -6.68 Million USD | 358.459% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -1423.633% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 304.352% |
| Peak Bio, Inc. | 10.34 Million USD | -67.096% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 120.963% |
| Krystal Biotech, Inc. | -350.23 Million USD | 104.933% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 86.08% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 110.224% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 647.267% |
| MannKind Corporation | 143.89 Million USD | 87.993% |
| Ikena Oncology, Inc. | -109.15 Million USD | 115.829% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 328.213% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 152.199% |
| Gossamer Bio, Inc. | 180.35 Million USD | 90.42% |
| CohBar, Inc. | -5.93 Million USD | 391.33% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 158.081% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -278.406% |
| Legend Biotech Corporation | -949.39 Million USD | 101.82% |
| Mural Oncology plc | -255.84 Million USD | 106.753% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 46.367% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 466.787% |
| Disc Medicine, Inc. | -358.28 Million USD | 104.822% |
| Champions Oncology, Inc. | 4.81 Million USD | -259.061% |
| REGENXBIO Inc. | 54.76 Million USD | 68.452% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 6525.27% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 111.441% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 291.722% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 121.415% |
| Vaxart, Inc. | -8.24 Million USD | 309.659% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 134.432% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 113.587% |
| Cellectis S.A. | -43.85 Million USD | 139.398% |
| Longeveron Inc. | -2.9 Million USD | 694.154% |
| Repare Therapeutics Inc. | -107.85 Million USD | 116.019% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 98.216% |
| Inozyme Pharma, Inc. | 12 Million USD | -43.935% |
| Revolution Medicines, Inc. | -608.2 Million USD | 102.841% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 1504.715% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 106.517% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 111.513% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 210.424% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 2434.865% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 100.181% |
| Denali Therapeutics Inc. | -74.86 Million USD | 123.079% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 244.083% |
| Veru Inc. | 4.77 Million USD | -261.467% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 253.637% |
| Cingulate Inc. | 3.08 Million USD | -460.486% |
| Passage Bio, Inc. | 4.58 Million USD | -276.838% |
| Context Therapeutics Inc. | -14.44 Million USD | 219.572% |
| Exicure, Inc. | 5.84 Million USD | -195.401% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 107.5% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 143.664% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | -10.114% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 129.374% |
| Nuvalent, Inc. | -335.38 Million USD | 105.152% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -896.229% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 123.198% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 294.353% |
| OmniAb, Inc. | 9.2 Million USD | -87.743% |
| Anew Medical, Inc. | 1.43 Million USD | -1106.173% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | -5.471% |
| Lipocine Inc. | -4.75 Million USD | 463.396% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 115.732% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | -13.44% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 134.106% |
| G1 Therapeutics, Inc. | 24.89 Million USD | 30.588% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 357.075% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 126.248% |
| Ocugen, Inc. | -32.52 Million USD | 153.129% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 120.19% |
| Q32 Bio Inc. | -37.94 Million USD | 145.531% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 2851.274% |
| Alumis Inc. Common Stock | -13.52 Million USD | 227.711% |
| Equillium, Inc. | -22.39 Million USD | 177.161% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 167.577% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 152.957% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 7069.324% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 87.11% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -440.275% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -5160.61% |
| Dominari Holdings Inc. | 195 Thousand USD | -8760.513% |
| Edesa Biotech, Inc. | -5.26 Million USD | 428.048% |
| vTv Therapeutics Inc. | -8.91 Million USD | 293.765% |
| Bio-Techne Corporation | 267.74 Million USD | 93.547% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 206.595% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 114.631% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 305.617% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 236.574% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 107.049% |
| Nkarta, Inc. | 57.29 Million USD | 69.846% |
| BioCardia, Inc. | 212 Thousand USD | -8050.0% |
| Iterum Therapeutics plc | 13.43 Million USD | -28.576% |